(Q40448458)

English

A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

based on heuristic

inferred from title

Daniel J. Hicklin

14

object named as

Daniel J Hicklin

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

author name string

Dan Lu

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Haifan Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Henry Koo

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

James Tonra

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Paul Balderes

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Marie Prewett

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Eric Corcoran

7

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Venkata Mangalampalli

8

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Rajiv Bassi

9

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Deborah Anselma

10

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Dipa Patel

11

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Xiaoqiang Kang

12

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Dale L Ludwig

13

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Peter Bohlen

15

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Larry Witte

16

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Zhenping Zhu

17

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

0 references

publication date

9 March 2005

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

Journal of Biological Chemistry

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

280

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

19665-19672

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Clinical trials of antibody therapy

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Immunotherapeutic perspective for bispecific antibodies

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Bispecific antibody conjugates in therapeutics

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

A revival of bispecific antibodies

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

The IGF-I receptor in cancer research

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Role of an anti-epidermal growth factor receptor in treating cancer

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death--proliferative and anti-apoptotic effects

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth factor I receptor expression

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Toward the production of bispecific antibody fragments for clinical applications

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

New protein engineering approaches to multivalent and bispecific antibody fragments

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Design and application of diabodies, triabodies and tetrabodies for cancer targeting

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

An efficient route to human bispecific IgG.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Design and production of novel tetravalent bispecific antibodies

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Bispecific human IgG by design

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Engineering high affinity humanized anti‐p185HER2/anti‐CD3 bispecific F(ab′)2 for efficient lysis of p185HER2 overexpressing tumor cells

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Di-diabody: a novel tetravalent bispecific antibody molecule by design

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M500815200

21 January 2018

Identifiers

10.1074/JBC.M500815200

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40448458&oldid=1770313948"